Clinical trial
Interleukin 12 (IL-12) for the Treatment of Cryptosporidiosis in AIDS Patients
NCT00057486 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Terminated
Key facts
| NCT number | NCT00057486 |
|---|---|
| Title | Interleukin 12 (IL-12) for the Treatment of Cryptosporidiosis in AIDS Patients |
| Official title | A Pilot, Proof-of-Concept, Dose-Escalating Trial of Recombinant Human Interleukin-12 (rhIL-12) Versus Placebo Along With Paromomycin and Azithromycin for Chronic Cryptosporidiosis in AIDS |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Status | Terminated |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | HIV Infections, Cryptosporidiosis |
| Intervention type | Drug |
| Interventions | IL-12 |
| Enrollment | 2 |
| Start date | Sep 1, 1997 |
| Primary completion | Jun 1, 2005 |
| Completion | Jun 1, 2005 |
| First posted | Apr 3, 2003 |
| Last update posted | Dec 14, 2016 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: